EUVIMEDEUVIMED entdecken
Scoping Review

Factors influencing the reimbursement of cancer drugs in Europe: A scoping review

Pelayo Nieto-Gómez iD, Celia Castaño-Amores iD

Journal of Evaluation in Clinical Practice · 2024-12 · 30 (8) · 1546-1555

DOI: 10.1111/jep.14080 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Journal of Evaluation in Clinical Practice, online erschienen am 03.07.2024. Verfasst von Pelayo Nieto-Gómez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Unit, Hospital Santa Bárbara, Puertollano, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Reimbursement Mechanisms, Cost-Effectiveness Analysis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Reimbursement process of oncology drugs in Europe occurs within a complex decision‐making process that varies between Member States. Distinctions between the States trigger societal debates since it is necessary to balance access to medicines and health systems sustainability. Aims and Objectives We aimed to review the evidence concerning factors associated with the reimbursement decision or Health Technology Agency recommendation of oncology drugs in Europe.

Methods

A systematic literature search was performed in two databases from inception to august 2023. Screening and data extraction were performed by pairs.

Results

Thirteen articles were included and encompassed data from 11 nations. Seven articles showed that cost‐effective (C‐E) drugs and lower Incremental Cost‐Effectiveness Ratios (ICERs) had higher likelihood of reimbursement. Disease severity might influence the reimbursement decision with financial agreements. Improvement in clinical outcomes, substantial clinical benefit ( p < 0.01) or overall survival gains ( p < 0.05) were positively associated. Orphan drug designation impact varies between countries but positive decisions are usually achieved under specific conditions. Clinical and C‐E uncertainty frequently led to reimbursement with financial agreements or outcomes‐based conditions. Sociodemographic factors as: social health insurance system, higher Gross Domestic Product and larger elderly population were positively associated with reimbursement ( p < 0.01).

Conclusion

There is a need for further research into key determinants of reimbursement decisions in Europe and the development of drug access models that can effectively address and overcome costs and effectiveness uncertainties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsReimbursement MechanismsCost-Effectiveness AnalysisHumansDecision MakingEuropeInsurance, Health, ReimbursementNeoplasmsOrphan Drug Production

Stichwörter der Autor:innen

evidence‐based medicinehealth economicshealth policyhealthcare organisationuncertaintyvalue

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacy Unit, Hospital Santa Bárbara, Puertollano, Spain.

ORCID-Profile: Pelayo Nieto-Gómez, Celia Castaño-Amores

Zitieren

APA

Nieto-Gómez, P., & Castaño-Amores, C. (2024). Factors influencing the reimbursement of cancer drugs in Europe: A scoping review. Journal of Evaluation in Clinical Practice, 30(8), 1546-1555. https://doi.org/10.1111/jep.14080

Vancouver

Nieto-Gómez P, Castaño-Amores C. Factors influencing the reimbursement of cancer drugs in Europe: A scoping review. Journal of Evaluation in Clinical Practice. 2024;30(8):1546-1555. doi:10.1111/jep.14080

BibTeX
@article{NietoGmez2024,
  author = {Nieto-Gómez, Pelayo and Castaño-Amores, Celia},
  title = {Factors influencing the reimbursement of cancer drugs in Europe: A scoping review},
  journal = {Journal of Evaluation in Clinical Practice},
  year = {2024},
  volume = {30},
  number = {8},
  pages = {1546--1555},
  doi = {10.1111/jep.14080}
}
Kostenlos starten →